A new combination of drugs might prolong life in certain older leukemia patients, a new study suggests. The research, led by German scientists, included nearly 800 older people (average age 73) who had been diagnosed with chronic ...
Tags: Drug, Drug Combo, Leukemia
ProteinSimple today introduced Wes, another revolutionary re-invention of the Western blot. Wes is the bold evolution of the popular Simple Western family of instruments, delivering simplicity and performance like no product before it. With ...
Tags: ProteinSimple, Wes, Western blot, re-invention, Simple Western
Zymeworks Inc. today announced that it has entered into a licensing and collaboration agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to develop an undisclosed number of novel bi-specific antibody ...
Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration ...
Tags: Bispecific Antibodies, Sutro's Cell-Free Protein Synthesis Technology
For the estimated 10 percent of patients whose bodies reject a corneal transplant, the odds of a second transplant succeeding are poor. All that could change, however, based on a UT Southwestern Medical Center study that has found a way to ...
Tags: corneal transplant, UT Southwestern Medical Center, interferon-gamma
Ann Marie Reynolds, a 32-year-old who has been in and out of hospitals fighting chronic kidney disease since she was a teenager, had a less than 1 percent chance of receiving a kidney without the University of Alabama at Birmingham's ...
Tags: chronic kidney disease, incompatible kidney exchange, kidney exchange
Scientists say they have the first definitive proof that a deadly respiratory virus in the Middle East infects camels in addition to humans. The finding may help researchers find ways to control the spread of the virus. Using gene ...
Tags: respiratory virus, camels, Middle East respiratory syndrome coronavirus
The flu vaccine is less effective for men than women, and researchers at Stanford University believe they've figured out why. The male hormone testosterone causes genes in the immune system to produce fewer antibodies, or defense ...
Tags: flu vaccine, male hormone, testosterone, the immune system, men health
Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents ...
US-based privately-held therapeutic antibody firm AnaptysBio has commenced an antibody development program with Momenta Pharmaceuticals, focused on the development of new antibodies against a therapeutically relevant target. Both the ...
Genzyme, a Sanofi company, has obtained an approval from Health Canada for its Lemtrada (alemtuzumab) for the treatment of relapsing remitting multiple sclerosis (RRMS). Health Canada has approved Lemtrada for the management of adult ...
Ventana Medical Systems (Ventana), a member of the Roche Group, has announced that its Ventana HER2/neu (4B5) rabbit monoclonal primary antibody assay is now a companion diagnostic for detecting HER2 protein expression for patients who, in ...
Tags: Ventana, Medical Systems
BioWa, a wholly owned subsidiary of Kyowa Hakko Kirin, and Lonza, a biotechnology company, have entered into a licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. MedImmune has licensed ...
Sutro Biopharma has received $26m in a Series D financing, which will be used for the expansion of its proprietary immuno-oncology product pipeline. The company is currently using its cell-free protein synthesis technology to develop new ...
Roche and Prothena have agreed to jointly develop and commercialize new antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease (PD). Currently, PRX002 is in ...